Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. by Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona

Get full text

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. by Andrea L Jorgensen, Richard J FitzGerald, James Oyee, Munir Pirmohamed, Paula R Williamson

Get full text

APOE Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program by Innocent G. Asiimwe, Andrea L. Jorgensen, Munir Pirmohamed, the Multimorbidity Mechanism and Therapeutic Research Collaborative (MMTRC)

Get full text

Interpreting results from biomarker-guided clinical trials: avoiding “negative” or “failed” terminology by Nurulamin M. Noor, Haiyan Zheng, David S. Robertson, Joshua Savage, Christina Yap, Andrea L. Jorgensen, James M. S. Wason, on behalf of the MRC-NIHR Trial Methodology Research Partnership (TMRP) Precision Medicine Working Group

Get full text

An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma by Pawan Gulati, Vickyanne Carruthers, Claire Hutton, Chloe Cassidy, Edward B. Amankwatia, Séréna Pascual, Electra Florence, Tsegay G. Gebru, Andrea L. Jorgensen, Alastair Greystoke, Guy Makin, Martin G. McCabe, Daniel B. Hawcutt, Gareth J. Veal, David Jamieson

Get full text